Sarah Johnson, Ph.D.

Assistant Professor of Medicine


BS, Biology/Biochemistry
Texas State University
San Marcos, Texas

PhD, Biochemistry/Molecular Biology
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Postgraduate Training

Post-doctoral Fellowship, Renal Pharmacology/Toxicology
Medical University of South Carolina
Charleston, South Carolina

Current Research

Dr. Johnson’s research is focused on understanding minimal residual disease (MRD) in myeloma. MRD represents the tumor cells that remain after chemotherapy and are most likely the source of relapse. The goal is to detect these resistant cells at the earliest stage possible so that they can be targeted along with the bulk tumor. To better understand this rare tumor cell population Dr. Johnson’s lab team detects and isolates them using multiparameter flow cytometry. The cells are subjected to molecular investigations such as next gen sequencing to elucidate the differences between MRD and tumors at presentation. Dr. Johnson is currently investigating these cells at the single-cell level to better understand the inherent heterogeneity present in each tumor and to identify new drug targets that will be effective against these resistant tumor cells.


Contact Information